Exenatide intranasal - Amylin
Alternative Names: Exenatide Nasal - AmylinLatest Information Update: 02 Oct 2021
At a glance
- Originator Amylin Pharmaceuticals
- Class Antihyperglycaemics; Obesity therapies; Peptides; Venoms
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (Intranasal, Spray)
- 08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb
- 10 Feb 2010 Phase-I development is ongoing